China National Accord Medicines Corporation Ltd.
国药一致
000028
Shenzhen Stock Exchange
Company Profile
The distribution business of Sinopharm Accord aims to become the leading provider for pharmaceutical distribution and supply chain service in southern China. Distribution of the Company provide comprehensive distribution, logistics and other value-added services for the manufacturers and suppliers of the domestic and foreign medicines, medical apparatus and instruments, consumables, other health care products, downstream hospitals, other distributors, retail pharmacies, and primary healthcare institution. At the same time, Distribution of the Company transformed and upgraded to be the leading provider of pharmaceutical supply chain solutions. We integrate the supply chain and the Internet to achieve innovation in health related industries such as medicine and health care, and explore the collaborative development of diversified businesses. In the pharmaceutical retail field, Sinopharm Holding Guoda Drugstores Co., Ltd. is a pharmaceutical retail enterprise that ranks the first in the sales volume throughout the country, and is one of the few enterprises in China with national direct sales drug retail network. Up to the date of disclosure, Guoda Pharmacy has established Regional chains over 18 provinces, autonomous regions and municipalities.In recent years, Guoda pharmacy has been developing in conformity with the social development, continuously improving the professional level, and developing the management service of diabetes and hypertension. Insist on service innovation; establish retail diagnosis innovation stores covering all kinds of pharmaceutical resources, including traditional Chinese medicine, western medicine and rehabilitation therapy. We aim to build a reliable Chinese pharmaceutical and healthcare retail brand.
Full description
The Company’s core businesses encompass (i) pharmaceutical distribution primarily focused on the Guangdong–Guangxi region, and (ii) a nationwide retail pharmacy network anchored by Guo Da Drugstore (“国大药房”). In addition, the Company holds equity stakes in selected pharmaceutical manufacturers. Details of each segment’s scope and operating model are set out below. 1. Pharmaceutical Distribution – Securing pharmaceuticals and medical devices supply to medical institutions while extending into Specialty Pharmacy Services The Company operates a unified, end-to-end procurement platform that sources finished pharmaceuticals and medical devices from domestic and international suppliers. By leveraging an integrated supply-chain covering logistics, warehousing and delivery throughout Guangdong–Guangxi region, the Company offers reliable product supply, inventory management, in-hospital logistics, emergency & low-volume product sourcing, and customized healthcare-service solutions and value-added services to all types of medical institutions (tertiary hospitals, community clinics, township health centers, CDCs, etc.) as well as to other retail pharmacies and sub-distributors. The Company also provides full-service market-access packages, portfolio management and innovative product-marketing support to suppliers. Building on its distribution capabilities and portfolio, the Company is extending into specialty pharmacy operations focused on novel drugs and chronic-disease therapies, supported by a professional patient-care system. 2. Retail Pharmacy – Nationwide network led by Guo Da Drugstore (“国大药房”) Guo Da Drugstore (“国大药房”), a subsidiary of the Company, is one of the largest retail pharmacy chains in China by sales. It operates a centralized procurement system and, through a nationwide network of directly operated stores across 18 provinces, autonomous regions and centrally administered municipalities, provides consumers with (i) prescription and OTC drugs, traditional Chinese medicine decoctions, medical devices, nutritional supplements, health foods and personal-care products; and (ii) medication counselling and integrated services such as Western medicine, traditional Chinese medicine, and rehabilitation therapy; and (iii) comprehensive health-management programs for members and chronic-disease patients. 3. Strategic Equity Investments in Pharmaceutical Manufacturers The Company holds minority stakes in selected pharmaceutical manufacturers, notably Shenzhen Main Luck Pharmaceuticals Inc. (“万乐药业”), Shanghai Shyndec Pharmaceutical Co Ltd (“国药现代”) and its subsidiaries Sinopharm Zhijun (Shenzhen) Pharmaceutical Co., Ltd (“国药致君”) & Sinopharm Zhijun (Shenzhen) Pingshan Pharmaceutical Co., Ltd. (“致君坪山”). These investees engage in the R&D, production and marketing of products covering anti-infectives, respiratory medicines, health supplements, traditional Chinese medicines and oncology therapies.